DTIL
Precision BioSciences, Inc.NASDAQHealthcare$5.82+2.28%ClosedMarket Cap: $74.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.84
P/S
2.25
EV/EBITDA
0.10
DCF Value
$-15.58
FCF Yield
-85.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.0%
Operating Margin
-152.2%
Net Margin
-136.0%
ROE
-97.0%
ROA
-30.2%
ROIC
-35.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $34.2M | 98.0% | $12.5M | $19.2M | $1.00 | — |
| FY 2025 | $34.3M | 92.0% | $-52.1M | $-46.6M | $-3.63 | — |
| Q3 2025 | $13.0K | -5084.6% | $-20.7M | $-21.8M | $-1.84 | — |
| Q2 2025 | $18.0K | -3766.7% | $-21.9M | $-23.5M | $-2.13 | — |
| Q1 2025 | $29.0K | 100.0% | $-22.1M | $-20.6M | $-2.29 | — |
| Q4 2024 | $638.0K | 100.0% | $-24.8M | $-17.7M | $-2.50 | — |
| FY 2024 | $68.7M | 100.0% | $-26.2M | $7.2M | $1.04 | — |
| Q3 2024 | $576.0K | 100.0% | $-21.3M | $-16.4M | $-2.25 | — |
| Q2 2024 | $49.9M | 100.0% | $24.1M | $32.7M | $4.67 | — |
| Q1 2024 | $17.6M | 100.0% | $-4.2M | $8.6M | $1.70 | — |
| Q4 2023 | $7.0M | 100.0% | $-14.9M | $-16.3M | $-3.66 | — |
| FY 2023 | $48.7M | 100.0% | $-43.7M | $-61.3M | $-15.96 | — |